Pacific Edge (NZE:PEB, ASX:PEB) reported total laboratory throughput of 7,092 tests for the fiscal third quarter ended December 2024, a 0.7% rise from the prior three-month period, according to a Wednesday filing with the Australian and New Zealand bourses.
Its sales force efficiency metric was flat at 379 tests per sales of a full-time employee. Tests per unique US ordering clinician was up 9.1% to 7.
The cancer diagnostics company plans to seek a preliminary injunction in the US relating to the removal of its flagship Cxbladder test from the coverage of Medicare contractor, Novitas.
Pacific Edge said this move is "on the basis of the irreparable harm" that Novitas' decision would cause its business if efforts to negotiate a withdrawal or revision fail, per the filing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.